Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 8/2005

01.08.2005 | Short Communication

Quantitative assessment of the long-term effect of photodynamic therapy in patients with pathologic myopia

verfasst von: Ute E. K. Schnurrbusch, Claudia Jochmann, Peter Wiedemann, Sebastian Wolf

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 8/2005

Einloggen, um Zugang zu erhalten

Abstract

Background

In patients with classic subfoveal choroidal neovascularization (CNV) secondary to pathologic myopia (PM), photodynamic therapy (PDT) has been shown to stabilize the visual acuity. We have analyzed the long-term visual prognosis after PDT in patients with CNV secondary to PM.

Methods

In a retrospective study we reviewed the clinical charts of 102 patients. PDT was performed following the procedures described in the VIP and TAP study protocols. Follow-up examinations and PDT treatment were scheduled in 3-month intervals. Indications for retreatment were an active leaking CNV in combination with visual disturbances or visual loss. To assess treatment effects we analyzed the number of letters read on the ETDRS charts. The primary efficacy outcome was the proportion of eyes that had fewer than eight letters loss or gain at 24 months. Secondary efficacy outcomes included the proportion of eyes that had fewer than 15 letters loss or gain and the proportion of eyes that had fewer than 30 letters loss or gain at month 24.

Results

One hundred and two patients were included into the study. Mean follow-up was 32.5±5.7 months. Patients received an average of 2.2 treatments from study entry through the last follow-up, resulting in a total of 221 PDT sessions throughout the study. At 24 months 46% lost at least eight letters. A loss of at least 15 (30) letters was observed in 25% (8%). Improvement of at least eight letters was noted in 8%. Larger improvements of at least 15 letters occurred only in 4% of study eyes.

Conclusion

Our study suggests that PDT can increase the chance of stabilizing or improving vision compared with the placebo arm of VIP trial.
Literatur
1.
Zurück zum Zitat Avila MP, Weiter JJ, Jalkh AE, Trempe CL, Pruett RC, Schepens CL (1984) Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 91:1573–1581PubMed Avila MP, Weiter JJ, Jalkh AE, Trempe CL, Pruett RC, Schepens CL (1984) Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 91:1573–1581PubMed
2.
Zurück zum Zitat Barnes RM, Gee L, Taylor S, Briggs MC, Harding SP (2004) Outcomes in verteporfin photodynamic therapy for choroidal neovascularisation—‘beyond the TAP study’. Eye 18(8):809–813CrossRefPubMed Barnes RM, Gee L, Taylor S, Briggs MC, Harding SP (2004) Outcomes in verteporfin photodynamic therapy for choroidal neovascularisation—‘beyond the TAP study’. Eye 18(8):809–813CrossRefPubMed
3.
Zurück zum Zitat Cohen SY, Bulik A, Dubois L, Quentel G (2003) Photodynamic therapy for juxtafoveal choroidal neovascularization in myopic eyes. Am J Ophthalmol 136(2):371–374CrossRefPubMed Cohen SY, Bulik A, Dubois L, Quentel G (2003) Photodynamic therapy for juxtafoveal choroidal neovascularization in myopic eyes. Am J Ophthalmol 136(2):371–374CrossRefPubMed
4.
Zurück zum Zitat Cohnen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ (1996) Etiology of choroidal neovascularization in young patients. Ophthalmology 103:1241–1244PubMed Cohnen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ (1996) Etiology of choroidal neovascularization in young patients. Ophthalmology 103:1241–1244PubMed
5.
Zurück zum Zitat Fardeau C, Soubrane G, Coscas G (1992) Photocoagulation des néovaisseax sousrétiniens compliquant la dégénérescence myopique. Bull Soc Ophtalmol Fr 92:239–242 Fardeau C, Soubrane G, Coscas G (1992) Photocoagulation des néovaisseax sousrétiniens compliquant la dégénérescence myopique. Bull Soc Ophtalmol Fr 92:239–242
6.
Zurück zum Zitat Hochkiss ML, Fine SL (1981) Pathologic myopia and choroidal neovascularization. Am J Ophthalmol 91:177–183PubMed Hochkiss ML, Fine SL (1981) Pathologic myopia and choroidal neovascularization. Am J Ophthalmol 91:177–183PubMed
7.
Zurück zum Zitat Jalkh AE, Weiter JJ, Trempe CL, Pruett RC, Schepens CL (1987) Choroidal neovascularization in degenerative myopia: role of laser photocoagulation. Ophthalmic Surg 18(10):721–725 Jalkh AE, Weiter JJ, Trempe CL, Pruett RC, Schepens CL (1987) Choroidal neovascularization in degenerative myopia: role of laser photocoagulation. Ophthalmic Surg 18(10):721–725
8.
Zurück zum Zitat Johnson DA, Yannuzzi LA, Shakin JL, Lightman DA (1998) Lacquer cracks following laser treatment of choroidal neovascularization in pathologic myopia. Retina 18:117–124 Johnson DA, Yannuzzi LA, Shakin JL, Lightman DA (1998) Lacquer cracks following laser treatment of choroidal neovascularization in pathologic myopia. Retina 18:117–124
9.
Zurück zum Zitat Lam DS, Chan WM, Liu DT, Fan DS, Lai WW, Chong KK (2004) Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year follow up. Br J Ophthalmol 88(10):1315–1319 Lam DS, Chan WM, Liu DT, Fan DS, Lai WW, Chong KK (2004) Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year follow up. Br J Ophthalmol 88(10):1315–1319
10.
Zurück zum Zitat Lanzetta P, Battaglia Parodi M, Ambesi-Impiombato M, Ravalico G, Bandello F (2004) Early neovascular bridging after photodynamic therapy of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 242(10):840–844 Lanzetta P, Battaglia Parodi M, Ambesi-Impiombato M, Ravalico G, Bandello F (2004) Early neovascular bridging after photodynamic therapy of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 242(10):840–844
11.
Zurück zum Zitat Montero JA, Ruiz-Moreno JM (2003) Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation. Br J Ophthalmol 87(2):173–176 Montero JA, Ruiz-Moreno JM (2003) Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation. Br J Ophthalmol 87(2):173–176
12.
Zurück zum Zitat Ruiz-Moreno JM, Montero JA (2003) Subretinal fibrosis after photodynamic therapy in subfoveal choroidal neovascularisation in highly myopic eyes. Br J Ophthalmol 87(7):856–859 Ruiz-Moreno JM, Montero JA (2003) Subretinal fibrosis after photodynamic therapy in subfoveal choroidal neovascularisation in highly myopic eyes. Br J Ophthalmol 87(7):856–859
13.
Zurück zum Zitat TAP Study Group (1999) Photodynamic therapy of subfoveoal choroidal veovascularization in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trials—TAP report 1. Arch Ophthalmol 117:1329–1345 TAP Study Group (1999) Photodynamic therapy of subfoveoal choroidal veovascularization in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trials—TAP report 1. Arch Ophthalmol 117:1329–1345
14.
Zurück zum Zitat TAP Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials—TAP report 2. Arch Ophthalmol 119(2):198–207 TAP Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials—TAP report 2. Arch Ophthalmol 119(2):198–207
15.
Zurück zum Zitat VIP Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial—VIP report no. 1. Ophthalmology 108(5):841–852 VIP Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial—VIP report no. 1. Ophthalmology 108(5):841–852
16.
Zurück zum Zitat VIP Study Group (2001) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin in photodynamic therapy. Report 2 Am J Ophthalmol 131:541–560 VIP Study Group (2001) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin in photodynamic therapy. Report 2 Am J Ophthalmol 131:541–560
17.
Zurück zum Zitat VIP Study Group (2003) Verteprofin therapy of subfoveal choroidal neovascularization in pathologic myopia. 2-year results of a randomized clinical trial—VIP Report No. 3 Ophthalmology 110:666–673 VIP Study Group (2003) Verteprofin therapy of subfoveal choroidal neovascularization in pathologic myopia. 2-year results of a randomized clinical trial—VIP Report No. 3 Ophthalmology 110:666–673
18.
Zurück zum Zitat VIP-Study Group (2003) Verteprofin therapy of subfoveal choroidal neovascularization in pathologic myopia. 2-year results of a randomized clinical trial—VIP Report No. 3 Ophthalmology 110:666–673 VIP-Study Group (2003) Verteprofin therapy of subfoveal choroidal neovascularization in pathologic myopia. 2-year results of a randomized clinical trial—VIP Report No. 3 Ophthalmology 110:666–673
Metadaten
Titel
Quantitative assessment of the long-term effect of photodynamic therapy in patients with pathologic myopia
verfasst von
Ute E. K. Schnurrbusch
Claudia Jochmann
Peter Wiedemann
Sebastian Wolf
Publikationsdatum
01.08.2005
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 8/2005
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-005-1147-4

Weitere Artikel der Ausgabe 8/2005

Graefe's Archive for Clinical and Experimental Ophthalmology 8/2005 Zur Ausgabe

Announcements

August 2005

Neu im Fachgebiet Augenheilkunde

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.